Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Nov 10 2025

0mins

Source: PRnewswire

Facility Commissioning: Armata Pharmaceuticals has officially commissioned its new cGMP manufacturing facility in Los Angeles, marking a significant milestone in its operations and readiness for clinical trials of phage-based therapeutics.
Production Readiness: The facility has completed full production runs without issues, enabling Armata to manufacture high-purity bacteriophage cocktails for upcoming clinical trials and potential commercial production.
Commitment to Domestic Manufacturing: The new facility underscores Armata's commitment to onshore manufacturing, aligning with federal efforts to secure the medicine supply chain and address the antimicrobial resistance crisis.
Future Plans: Armata aims to advance its clinical candidate AP-SA02 into a pivotal Phase 3 trial in 2026, pending FDA review, while also exploring opportunities for partnering and contract manufacturing.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free